Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib
Ojemda (tovorafenib) FDA approval, pediatric oral suspension formulation, specialty pharmacy distribution, and landmark EU Joint Clinical Assessment.